Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023
The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus ...
Jaguar Health’s Napo granted FDA Type C Meeting to discuss OnTarget study
Jaguar Health (JAGX) announced that the U.S. Food and Drug Administration has granted Napo a Type C Meeting in the second quarter of 2025 to ...
Sacramento Bee5d
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
The statistically significant responder analysis results for Mytesi ® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 ...
Nature2mon
Is the ONTARGET renal substudy actually off target?
In ONTARGET patients, glomerular filtration rate (GFR) decline averaged 0.9 ml/min per year, which is within the physiologic range of GFR loss (0.6–1.1 ml/min per year) observed in healthy ...
Sacramento Bee18d
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders
As announced, the analysis of the prespecified subgroup of adult patients with breast cancer from the Company's recently conducted Phase 3 prophylactic OnTarget clinical trial for diarrhea in ...
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
"As a cancer patient, having options to manage the side effects of life saving drugs is very important. I believe the published results of crofelemer for the prophylaxis of CTD are very exciting and ...